Weekly evidence changelog

What Changed This Week

Week of July 6-12, 2026Generated Jul 10, 2026

A weekly summary of studies, interventions, outcomes, and evidence relationships added to Dediabetes.

Changes reflect content added to Dediabetes during this week and may include studies published earlier.

148

New Studies

810

New Evidence Relationships

New Interventions

308

New Outcomes

Evidence Upgrades

Evidence Downgrades

Featured

Notable Changes

The most notable evidence graph changes detected in this weekly snapshot.

Notable Change

Aspirin -> Bleeding events

MedicationsSafety

New evidence relationship detected from studies added this week.

1 new supporting study·1 total supporting study

View evidence

Notable Change

Aspirin -> Blood lactate concentration

MedicationsMetabolic Health

New evidence relationship detected from studies added this week.

1 new supporting study·1 total supporting study

View evidence

Notable Change

Aspirin -> Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

MedicationsClinical Outcomes

New evidence relationship detected from studies added this week.

1 new supporting study·1 total supporting study

SupplementsMetabolic Health

New evidence relationship detected from studies added this week.

1 new supporting study·1 total supporting study

View evidence

This study evaluated the impact of telemedicine-assisted structured self-monitoring of blood glucose on glycemic control in adults with type 2 diabetes, finding significant improvements in HbA1c and other metrics.

Standard care with capillary blood glucose monitoringTraditional blood glucose meter (BGM)Blood glucose+2 more

View study

Entities

New Interventions & Outcomes

New intervention and outcome entities created during this weekly snapshot.

New Interventions

Cocoa supplementationCurcuma longa extract (CLE)Date Seed Powder (DSP)Non-surgical periodontal treatmentNon-surgical periodontal treatment + Zinc gluconate and Magnesium oxidePrebiotic supplementationPurified anthocyanins supplementationSodium ButyrateSumac supplementBeaT-2/SugarburnerChromium supplementationCinnamomum zeylanicumDeep seawater mineral extracts containing Mg 2+Dietary fibre supplement (YMETA)EldecalcitolEndurance exerciseExtra virgin olive oil supplementationStandard type 2 diabetes medication treatment, unspecifiedZinc supplementationCanagliflozin combined with MetforminMetformin combined with PlaceboTicagrelor monotherapy after 3 months of DAPTClazakizumabErtugliflozinHigh-dose inactivated influenza vaccine (HD-IIV)Icosapent ethylIntensive glycemic controlMultifactorial Therapy (MT)Multifactorial interventionsOral multivitamins and multiminerals (OMVM)OrforglipronStandard glycemic controlStandard-dose inactivated influenza vaccine (SD-IIV)Glow app for type 2 diabetes educationMotivation Enhancement SystemQuestion Prompt ListReducing Emotional Distress for Childhood Hypoglycemia in Parents (REDCHiP)Standard care with capillary blood glucose monitoringStandard face-to-face caremHealth diabetes support interventionmHealth dietary education interventionmHealth intervention with personal feedbackDiabeTextDialBetesPlus mobile health interventionHealth Storylines mAPPHealthy PregnancyKeeping in Touch (KiT)Mobile app for diabetes self-managementMobile educational platformMulberry leaf extract (MLE) blendSmartphone applications for oral hygiene and glycemic controlStructured food sequencing with mHealth monitoringTelehealth coaching for patients with T2DM and/or CHDTelehealth interventionTelephone Follow-UpTraditional pamphletType 1 Diabetes and Life (T1DAL) interventionVA|PREVENTION project web application with virtual human coachVitadio digital therapyTIME (Telehealth-supported Integrated Community Health Workers) - Active TreatmentTraditional blood glucose meter (BGM)

New Outcomes

Hyaluronic acid (HA)Matrix metalloproteinase-2 (MMP-2)Neuropathy symptom scoreSyndecan-1 (SDC1)Syndecan-4 (SDC4) carboxymethyl-lysine (CML)Abdominal PainBloatingHOMA-BHOMA-IR IndexLactulose Hydrogen Breath Test ResultsLipopolysaccharide (LPS)Matrix metalloproteinase-9 (MMP-9)Nuclear factor erythroid 2-related factor 2 (Nrf2)Nuclear factor kappa B (NF-κB p65)PentosidinePlatelet activationSerum CXCL-10Serum IFN-γSerum IL-18Sirtuin-1 (SIRT1)Thioredoxin-1 (Trx1)Thioredoxin-binding protein-2 (TBP2)Total 25-OH vitamin DUric AcidVery low-density lipoproteins (VLDL)s-RAGEAdvanced glycation end products (AGEs)Advanced oxidation protein products (AOPP)BEST scoreBleeding on probingDentobacterial plaque indexFIB-4 indexPeriodontal inflamed surface areaSerum CCL-11Serum CCL-2Serum CCL-5Serum CXCL-12Serum PF-4Serum ferritinSerum vitamin D3 levels (Placebo)Serum γ-GTToronto Clinical Scoring System (TCSS)Total 25-OH vitamin D levels (Placebo)Type IV collagenAdiposity indicesBone mineral content (BMC)Bone mineral density (BMD)Bone mineral density (BMD) at femoral neckButyrate-producing bacteriaErythrocyte sedimentation rateGCF ChemerinGingival Index (GI)Glutathione (GSH)Glutathione (GSH) (Placebo)Intact proinsulinMalondialdehyde (MDA) (Placebo)Nitric Oxide (NO) PlaceboOptical coherence tomographyOptical coherence tomography angiographyPlaque Index (PI)Serum ChemerinSkeletal muscle indexVery-low-density lipoprotein cholesterolBone mineral density (BMD) at distal radiusCortical pore diameter (Ct.Po.Dm) at radiusCortical pore diameter (Ct.Po.Dm) at tibiaCortical thickness (Co.Th)Intra-cortical porosity (Ct.Po)PTP1B expressionRegression to normoglycaemiaSerum GSH levels in control groupSerum IL-8Serum IL-8 levels in control groupSerum MCP-1Serum MCP-1 levels in control groupStressTrabecular thickness (Tb.Th)Ankle painFrequency of abortionKnee painLeg painRegression to normoglycaemia (placebo)Serum osteocalcinStumvoll insulin sensitivity indexBlood parametersGestational age at delivery (weeks)Insulin requirement during the interventionNICU requirement percentageRate of neonates with more than one complicationBleeding eventsHeart failure hospitalizationsLoss of vision likely due to retinopathyTime to cardiovascular deathTime to first nonfatal myocardial infarction eventCoronary revascularizationHemorrhagic strokeHospitalization for unstable anginaIncidence of non-cardiovascular deathIncidence of severe adverse reactionsIncidence of strokeIschemic strokeMajor kidney disease events composite including kidney or cardiovascular deathMajor kidney disease events composite including kidney or cardiovascular death (Placebo)Stroke recurrenceAcute pancreatitisApolipoprotein B changeApolipoprotein C3 changeDeathsHospitalization for any cardiorespiratory diseaseHospitalizationsHospitalizations for angina or revascularizationIncidence of vascular events within 90 daysInterleukin-6 changeModified Rankin Scale score ≤ 1Percentage of participants achieving blood pressure targetPneumoniaSymptomatic intracranial hemorrhageangiotensin (1-7)angiotensin-converting enzyme 2 (ACE2)lipoprotein(a)Hospitalization for any cardiovascular diseaseHospitalization for influenzaAdherence rate (MARS-5)Cardiovascular mortalityHospitalization for heart failurePill count adherenceCardiovascular deathComposite cardiovascular outcomeHeart failure compositeNonfatal strokePBMC maximal oxygen consumption ratePlasma IL-1BPlasma ketonesUrgent medical visit for heart failureAbsolute cardiovascular risk reductionArrhythmia composite outcomeChange in vascular regenerative cell content (ALDH hi SSC low)Global myocardial strainMajor adverse cardiovascular events, 5-point compositePlasma hsCRPT2 relaxation time changeendothelial precursors (ALDH hi SSC low CD34 + CD133 + CD45)granulocyte precursors (ALDH hi SSC hi)pan-haematopoietic myeloid progenitors (ALDH hi SSC low CD45 +)serum proteins involved in pro-inflammatory pathwaysAtherothrombotic eventsComposite of CV death, non-fatal myocardial infarction, or non-fatal strokeControlled attenuation parameterGlobal longitudinal strainIncidence of hyperkalemiaLiver stiffness measureProportion of subjects with hs-CRP < 2 mg/LTime to kidney failure, sustained eGFR decline ≥40% from baseline, or kidney-related deathhs-CRP (Placebo)left ventricular E/e' ratioAnnual rate of change in eGFRRelative risk reduction for major renal eventsTotal worsening heart failure events and death from cardiovascular causesMajor kidney disease events composite including end-stage renal disease, sustained eGFR decline, and death from renal or cardiovascular causesAcceptability of text messages in diabetes managementBlood pressure as a measure of cardiovascular riskChange in mean daily insulin units from baselineFall incidenceImprovement in social connectivity scoresIncrease in clinic visits during intervention phaseParental Fear of HypoglycemiaPatient-reported health care communication assessed via CAHPS scoresReduced sedentary timeReduction in acute unscheduled care visits during intervention phaseReduction in acute unscheduled care visits post-intervention phaseSedentary behaviorAdherence to Purposeful ExerciseLifestyle behaviorsPatient engagementPercentage contribution of ultra-processed foods to total energy intakeRecruitment RateUPF percentage contribution to total energy intake at baselineUPF percentage contribution to total energy intake at follow-upAcceptability of mHealth interventionAverage daily dose of antidiabetic medications required by participantsChange in physical fitness after 12 weeksChange in self-reported perceived health statusDepressive symptoms score in control groupDiabetes burnout (control group)Diabetes burnout scoresDiabetes distress scoresDirect non-health care costsFidelity of mHealth interventionImprovement in diabetes-related helpful family involvementImprovement in glycemic control for newly diagnosed patientsPerceived behavior change needsSafety eventsTotal costs in telemedicine group compared to standard careAcceptability of Motivation Enhancement SystemAcceptability of SMS Text Messaging Reminder among Emerging AdultsDiabetes self-care exercise scoreDiabetes self-care glucose testing scoreDiabetes social supportFrequency of perinatal complicationsGeneral Health Management ImprovementHealth Literacy ImprovementPatient ActivationReduction in indirect costsRelevance of Question Prompt ListSelf-reported behavioral change mechanismsUnderstanding of type 2 diabetesAdherence to Mediterranean diet measured using MEDAS-14Change in EsDQOL satisfaction scoreChange in General Diet Self-Care ScoreCompletion of HbA1c testing by 1 year postpartumEsDQOL satisfaction score (control)Improvement in Work-Life BalanceMedication possession ratio at 12 monthsPositivityProportion of participants with better glycemic controlProportion of participants with good medication adherenceSelf-reported medication adherence at 12 monthsChallenges in Consistently Applying REDCHiP StrategiesCompletion of HbA1c testing by 12 weeks postpartumDaily intake of saturated fat in gramsDaily intake of unsaturated fat in gramsFrequency of Coping Strategies Used by Parents to Manage Hypoglycemia FearFrequency of Parent-Reported Use of Cognitive Behavioral Therapy SkillsImplementation of Behavioral Parenting StrategiesImprovement in Transition Readiness for Adult CareNormal deliveriesNumber of NICU admissionsOverall diet quality measured using Nordic Nutrition Recommendation scoreOverall perceived quality of the acT1ve appParent Appreciation of REDCHiP Intervention ContentPercentage of participants who scheduled a visit with a primary care provider by 12 weeks postpartumPercentage of time spent above 10.0 mmol/LPercentage of time spent with sensor glucose levels <3.9 mmol/LPsychological DistressReduction in red meat intakeShoulder dystocia casesAreas for improvement in telehealth componentsConfidence-enhancing message ratingCustomization preference for message frequencyDiet and activity support effectivenessEngagement in Farm WorkMessage relevance ratingMessages flagged for revision by expert panelNeonatal complicationsOdds of helping with household choresOdds of stair useOdds of walking for choresParticipants' satisfaction evaluation of the APPPatient-reported foot care improvement at 6 monthsResponsiveness to medical and behavioral factors influencing self-managementSelf-management support effectivenessTotal Oral Health Value ScaleDental Neglect Scale ScoreDiabetes Distress Scale scoreGoal completion rateMean self-efficacy scorePercentage of Days Coping Strategies AppliedPost-test self-management scoreSelf-regulation measured using the Physical Activity Self-Regulation ScaleTotal oral hygienic behaviorsChild satisfaction score regarding diabetes interventionComposite of Weight, Physical Activity, and Dietary GoalsImprovements in dietary habitsParent satisfaction score regarding diabetes interventionProportion of participants breastfeeding at 1 monthProportion of participants breastfeeding at 6 monthsProportion of participants meeting dietary goalProportion of participants meeting weight goalProportion of participants who had an OGTT performed by 12 weeks postpartumReduction in child-reported diabetes distress as measured by the PAID scoreTotal physical activity time in minutes per weekWeight loss at 24 months in control groupWeight loss at 6 monthsFollow-up assessment resultsImprovement in dietary behaviorImprovement in foot care behaviorImprovement in foot conditionMedical record data availability at 6 monthsOverall training informativeness ratingParticipant retention at 6 monthsPreference for In-Person TrainingProportion of participants with EPDS score ≥ 10Rate of recruitment to randomisationRecruitment/enrollment/retention ratesSelf-report data availabilityUsefulness of Motivational Interviewing and Health Action Process Approach in TrainingChange in liver enzymes (GGT)Difference in Thai-CV risk score at 12 months compared to routine careFecal levels of phenolic metabolitesGlucagonIncrease in Healthy Eating Days per WeekIncremental area under the curve for postprandial glucose at 2 hoursLog-transformed reactive hyperemia index (LnRHI)Postprandial GIP incremental area under the curve (iAUC)Qualitative feedback on behavioral interventionReduction in Gingival Bleeding Index following SRP and Vitamin D supplementationTOI hyperemic responseTissue Oxygen Index (TOI) RangeAttrition Rate of the InterventionChange in aortic pulse wave velocity from baseline to week 24Percentage of SMS text message responses reporting hypoglycemia (<80 mg/dL)Percentage of patients discharged on maximum GLP-1 RA dosePercentage of patients with GLP-1 RA dose increased by at least one levelPercentage of patients with insulin dose reduction by at least 50%Percentage of patients with insulin stopped completelyPlasma arginine levelsVideo watch rate

EvidenceScore™

EvidenceScore™ Changes

No EvidenceScore™ changes were detected this week.

Latest Research

Browse recently published studies.

Browse ->

Newsletter signup

Get the Weekly Diabetes Research Digest.

Browse ->

Browse Archive

Explore the full evidence archive.

Browse ->